In this video, health-care analyst David Williamson takes a look at the tremendous success of the Bluebird Bio (BLUE -1.07%) IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Bluebird doesn't have any products in late stage trials, but its three drug-development programs are extremely intriguing. Is the hype for its shares justified, or is this another sign of a biotech bubble? And would investors possibly be better served taking a look at Bluebird's partner Celgene (CELG)?
Watch and find out.
Follow David on Twitter: @MotleyDavid.
